Liraglutide Attenuates Diabetic Cardiomyopathy via the ILK/PI3K/AKT/PTEN Signaling Pathway in Rats with Streptozotocin-Induced Type 2 Diabetes Mellitus

Liraglutide Attenuates Diabetic Cardiomyopathy via the ILK/PI3K/AKT/PTEN Signaling Pathway in Rats with Streptozotocin-Induced Type 2 Diabetes Mellitus

One of the possible candidates for the treatment of diabetic cardiomyopathy is liraglutide, a glucagon-like peptide-1 receptor (GLP1R) agonist. In this study, the impacts of liraglutide on the integrin-linked kinase (ILK)-related PI3K/AKT axis in rats with type 2 diabetes induced via streptozotocin...

Full description

Bibliographic Details
Main Authors: Shatha M. Alobaid, Rahaf M. Alshahrani, Asma S. Alonazi, Nawal M. Alrasheed, Maha A. Alamin, Tahani K. Alshammari, Anfal F. Bin Dayel, Doaa M. Elnagar, Rana R. Alotaibi, Lama A. Almuthnabi, Dalia H. Almasud, Shahad E. Al-Ammar, Shahad O. Almadhi, Reema A. Almalke, Nouf T. Aldamri, Hanan K. Alghibiwi, Dalal A. Alkhelb, Nouf M. Alrasheed
Format: Article
Language:English
Published: MDPI AG 2024-03-01
Series:Pharmaceuticals
Subjects:
glucagon-like peptide-1 analog
diabetic cardiomyopathy
streptozotocin-induced type 2 diabetes
integrin-linked kinase
phosphatidylinositol 3-kinase
protein kinase B
Online Access:https://www.mdpi.com/1424-8247/17/3/374

Internet

https://www.mdpi.com/1424-8247/17/3/374

Similar Items